Wanbangde Pharmaceutical Holding Group Co., Ltd. (SHE:002082)
China flag China · Delayed Price · Currency is CNY
9.27
-0.15 (-1.59%)
Sep 10, 2026, 12:45 PM CST

SHE:002082 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,1271,1171,4271,5311,7701,923
Other Revenue
0.710.7116.1110.5116.467.86
1,1281,1171,4431,5421,7861,931
Revenue Growth
-11.15%-22.59%-6.39%-13.69%-7.47%-85.91%
Cost of Revenue
671.55737.1847.18918.18852.57999.27
Gross Profit
456.03380.23596.19623.76933.85931.33
Selling, General & Admin
348.09374.84443.02458.13579.71571.77
Research & Development
52.9759.1659.8753.9859.176.2
Other Operating Expenses
57.6315.1317.5417.8923.4820.43
Operating Expenses
529.18519.61519.54553.57701.27720.65
Operating Income
-73.14-139.3876.6570.19232.58210.69
Interest Expense
-38.08-38.08-38.5-46.48-33.2-35.6
Interest & Investment Income
14.8911.7918.975.1910.75235.76
Currency Exchange Gain (Loss)
1.81.8-0.05-4.53-0.82-0.93
Other Non Operating Income (Expenses)
-7.22-2-1.84-1.41-0.74-1.27
EBT Excluding Unusual Items
-101.74-165.8655.2322.96208.58408.65
Impairment of Goodwill
-----67.78-19.27
Gain (Loss) on Sale of Investments
8.2210.452.94-1.83-0.56-2.39
Gain (Loss) on Sale of Assets
0.30.615.740.12-0.95-1.21
Asset Writedown
-7.76-6.13-21.75-2.88-22.5-28.09
Other Unusual Items
1.721.726.811.56-16.663.46
Pretax Income
-99.27-159.2358.9529.93100.13361.14
Income Tax Expense
24.3212.6713.713.626.43199.98
Earnings From Continuing Operations
-123.58-171.945.2526.3373.71161.16
Minority Interest in Earnings
6.164.6610.1922.8819.555.35
Net Income
-117.42-167.2455.4449.2193.26166.51
Net Income to Common
-117.42-167.2455.4449.2193.26166.51
Net Income Growth
--12.67%-47.23%-43.99%-41.56%
Shares Outstanding (Basic)
588619616615622617
Shares Outstanding (Diluted)
588619616615622617
Shares Change
-8.63%0.55%0.15%-1.06%0.82%1.73%
EPS (Basic)
-0.20-0.270.090.080.150.27
EPS (Diluted)
-0.20-0.270.090.080.150.27
EPS Growth
--12.50%-46.67%-44.44%-42.55%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
482.54302.3323.11-201.59-406.88-263.42
Free Cash Flow Per Share
0.820.490.04-0.33-0.65-0.43
Dividend Per Share
---0.0800.120-
Dividend Growth
----33.33%-40.00%-
Gross Margin
40.44%34.03%41.30%40.45%52.28%48.24%
Operating Margin
-6.49%-12.47%5.31%4.55%13.02%10.91%
Profit Margin
-10.41%-14.97%3.84%3.19%5.22%8.63%
Free Cash Flow Margin
42.79%27.06%1.60%-13.07%-22.78%-13.64%
EBITDA
44.69-38.26177.72163.98337.3305.12
EBITDA Margin
3.96%-3.43%12.31%10.63%18.88%15.80%
D&A For EBITDA
117.83101.11101.0793.79104.7294.43
EBIT
-73.14-139.3876.6570.19232.58210.69
EBIT Margin
-6.49%-12.47%5.31%4.55%13.02%10.91%
Effective Tax Rate
--23.25%12.04%26.39%55.37%
Revenue as Reported
1,1171,1171,4431,5421,7861,931
Advertising Expenses
-0.861.493.731.324.86